WO2004050828A3 - Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer - Google Patents

Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer Download PDF

Info

Publication number
WO2004050828A3
WO2004050828A3 PCT/US2002/038264 US0238264W WO2004050828A3 WO 2004050828 A3 WO2004050828 A3 WO 2004050828A3 US 0238264 W US0238264 W US 0238264W WO 2004050828 A3 WO2004050828 A3 WO 2004050828A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
useful
detection
treatment
nucleic acid
Prior art date
Application number
PCT/US2002/038264
Other languages
English (en)
Other versions
WO2004050828A2 (fr
Inventor
Arthur B Raitano
Karen Jane Meyrick Morrison
Wangmao Ge
Pia M Challita-Eid
Aya Jakobovits
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to EP02789937A priority Critical patent/EP1565200A4/fr
Priority to JP2004557078A priority patent/JP2006508163A/ja
Priority to PCT/US2002/038264 priority patent/WO2004050828A2/fr
Priority to AU2002352976A priority patent/AU2002352976B2/en
Priority to CA2503346A priority patent/CA2503346C/fr
Publication of WO2004050828A2 publication Critical patent/WO2004050828A2/fr
Publication of WO2004050828A3 publication Critical patent/WO2004050828A3/fr
Priority to IL167892A priority patent/IL167892A/en
Priority to AU2008200628A priority patent/AU2008200628B2/en
Priority to AU2009208065A priority patent/AU2009208065B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un nouveau gène 024P4C12 (également nommé 24P4C12), sa protéine codée, ainsi que ses variants. Le gène 24P4C12 présente une expression tissulaire spécifique pour un tissu adulte normal, et est exprimé de manière aberrante dans les cancers énumérés dans la Table I. Le 24P4C12 constitue une cible diagnostique, pronostique, prophylactique et/ou thérapeutique contre le cancer. Le gène 24P4C12 ou un fragment de celui-ci, ou sa protéine codée, ou des variants ou un fragment de celle-ci, peuvent être utilisés pour déclencher une réponse immunitaire humorale ou cellulaire, et des anticorps ou des lymphocytes T réagissant avec le 24P4C12 peuvent être utilisés dans l'immunisation active ou passive.
PCT/US2002/038264 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer WO2004050828A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP02789937A EP1565200A4 (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer
JP2004557078A JP2006508163A (ja) 2002-11-27 2002-11-27 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
PCT/US2002/038264 WO2004050828A2 (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer
AU2002352976A AU2002352976B2 (en) 2002-11-27 2002-11-27 Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
CA2503346A CA2503346C (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer
IL167892A IL167892A (en) 2002-11-27 2005-04-06 Nucleic acid and protein entitled 24p4c12 and compositions containing the same and uses thereof
AU2008200628A AU2008200628B2 (en) 2002-11-27 2008-02-08 Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
AU2009208065A AU2009208065B2 (en) 2002-11-27 2009-08-07 Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/038264 WO2004050828A2 (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer

Publications (2)

Publication Number Publication Date
WO2004050828A2 WO2004050828A2 (fr) 2004-06-17
WO2004050828A3 true WO2004050828A3 (fr) 2004-12-09

Family

ID=32467113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038264 WO2004050828A2 (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer

Country Status (6)

Country Link
EP (1) EP1565200A4 (fr)
JP (1) JP2006508163A (fr)
AU (3) AU2002352976B2 (fr)
CA (1) CA2503346C (fr)
IL (1) IL167892A (fr)
WO (1) WO2004050828A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2185574T3 (pl) * 2007-09-07 2013-09-30 Agensys Inc Przeciwciała i powiązane cząsteczki, które wiążą się do białek 24P4C12
KR20120034591A (ko) * 2009-03-06 2012-04-12 어젠시스 인코포레이티드 24ｐ4ｃ12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
JP2013049646A (ja) * 2011-08-30 2013-03-14 Tokyo Medical Univ 癌治療剤
CA3000275A1 (fr) 2015-10-02 2017-04-06 University Of Copenhagen Petites molecules bloquant les domaines lecteur d'histone
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
JP7184259B2 (ja) * 2017-04-28 2022-12-06 学校法人藤田学園 アレルギーの抗原およびそのエピトープ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147904A1 (en) * 1999-04-12 2003-08-07 Afar Daniel E. Novel 13-transmembrane protein expressed in prostate cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2044593C (fr) 1989-11-03 2004-04-20 Kenneth L. Brigham Methode d'expression in vivo de genes etrangers fonctionnels
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
JP2001504799A (ja) 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
JP2001512013A (ja) * 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
EP2365081A3 (fr) * 1999-04-12 2012-07-18 Agensys, Inc. Protéine à treize segments transmembranaires exprimée dans le cancer de la prostate
CA2395007A1 (fr) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporteurs et canaux ioniques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147904A1 (en) * 1999-04-12 2003-08-07 Afar Daniel E. Novel 13-transmembrane protein expressed in prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1565200A4 *

Also Published As

Publication number Publication date
EP1565200A2 (fr) 2005-08-24
AU2009208065A1 (en) 2009-08-27
AU2002352976B2 (en) 2007-11-08
IL167892A (en) 2012-06-28
CA2503346C (fr) 2014-03-18
AU2002352976A1 (en) 2004-06-23
AU2008200628B2 (en) 2009-05-07
CA2503346A1 (fr) 2004-06-17
EP1565200A4 (fr) 2009-06-24
WO2004050828A2 (fr) 2004-06-17
JP2006508163A (ja) 2006-03-09
AU2008200628A1 (en) 2008-03-06
AU2009208065B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
WO2003022995A3 (fr) Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
WO2003040340A3 (fr) Acide nucleique et proteine correspondante 161p2f10b utiles dans le traitement et le depistage du cancer
WO2004016799A3 (fr) Acides nucleiques et proteines correspondantes intitulees 191p4d12(b) utilises dans le traitement et la detection du cancer
ZA200509606B (en) Prostate stem cell antigen (PSCA) variants and subsequences thereof
IL181218A0 (en) Nucleic acids and corresponding 58p1d12 proteins for use in the detection and treatment of cancer
WO2005118864A3 (fr) Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)
CY1113064T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 184ρ1ε2 χρησιμα στη θεραπεια και ανιχνευση καρκινου
WO2003050255A3 (fr) Acide nucleique et proteine correspondante appelee 193p1e1b utile dans le traitement et la detection du cancer
WO2004098515A3 (fr) Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer
WO2002072785A3 (fr) Acide nucleique et proteine correspondante denommes 125p5c8 utiles dans le traitement et la detection de cancers
WO2004067716A3 (fr) Acides nucleiques et proteines correspondantes dites 254p1d6b utiles pour la detection et le traitement du cancer
WO2002060953A3 (fr) Acide nucleique et proteine transporteur de zinc codee intitules 108p5h8 utiles dans le traitement et la detection du cancer
WO2002083928A3 (fr) Acide nucleique et proteine correspondante intitule 158p3d2 utiles dans le traitement et la detection du cancer
WO2006055004A8 (fr) Acides nucléiques et protéines correspondantes désignés par 158p3d2, et pouvant être employés dans le traitement et la détection de cancers
WO2004050828A3 (fr) Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer
WO2002092842A3 (fr) Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers
WO2002095009A3 (fr) Acide nucleique et proteine correspondante, appelee 121p1f1, utilisee dans le traitement et le depistage du cancer
WO2004021977A3 (fr) Acide nucleique et proteine correspondante denommes 98p4b6, pour traitement et detection du cancer
WO2003085081A3 (fr) Acide nucleique et proteine correspondante appelee 238p1b2 utile dans le traitement et la detection du cancer
WO2002083068A8 (fr) Acide nucleique et proteine correspondante appele 121p2a3 utile pour le traitement et la detection des cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 167892

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2503346

Country of ref document: CA

Ref document number: 2002789937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002352976

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004557078

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002789937

Country of ref document: EP